Drugs

Article	Citations
Acknowledgement to Referees	497
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	472
Targeting DNA Damage Response Deficiency in Thoracic Cancers	288
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	254
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	247
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	224
Eftrenonacog Alfa: A Review in Haemophilia B	196
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	167
Teclistamab: First Approval	164
Aprocitentan: First Approval	156
New Therapies on the Horizon for Primary Biliary Cholangitis	146
Senaparib: First Approval	144
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	142
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	139
Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms	128
Vorasidenib: First Approval	125
Spesolimab for the Treatment of Generalized Pustular Psoriasis	124
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,	108
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	103
Epcoritamab: First Approval	103
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	102
Repotrectinib: First Approval	101
Drugs in Development to Manage Acute Pain	93
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	91
Lenacapavir: First Approval	91

Tolebrutinib: First Approval	90
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms	88
Ivarmacitinib Sulfate: First Approval	87
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	85
Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses	84
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	82
Cosibelimab: First Approval	82
Danicopan: First Approval	82
Androgenetic Alopecia: Therapy Update	79
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	79
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	78
Acoltremon: First Approval	76
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	76
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	70
Cancer Pain Treatment Strategies in Patients with Cancer	69
Sibeprenlimab: First Approval	68
Mazdutide: First Approval	68
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	67
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	66
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	66
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema	65
Mosunetuzumab: First Approval	64
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	63
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?	63
Pozelimab: First Approval	62
Tovorafenib: First Approval	59
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	58
Correction to: Tapinarof Cream 1%: First Approval	58
Pixavir Marboxil: First Approval	57
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	57
Managing Burning Mouth Syndrome: Current and Future Directions	57
The Place of Cannabinoids in the Treatment of Gynecological Pain	57
Correction to: Prevention and Treatment of Monkeypox	56
Ifupinostat: First Approval	55
Taletrectinib: First Approval	53
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	52
Targeting Inflammation in Bronchiectasis	49
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	48
Dorzagliatin: First Approval	48
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	47
Sunvozertinib: First Approval	47
Correction to: Concizumab: First Approval	47
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	46
Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies	46
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	46
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	45
Correction to: Remdesivir: A Review in COVID-19	45
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	44
Gepirone Extended-Release: First Approval	43
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	43

Advances in Immune-Based Approaches for the Cure of HIV Infection	42
Ozoralizumab: First Approval	42
Tirzepatide: A Review in Type 2 Diabetes	42
Birch Bark Extract: A Review in Epidermolysis Bullosa	41
Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades	41
Givinostat: First Approval	41
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	41
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	41
Pan-JAK Inhibition Across Chronic Hand Eczema and Other Cutaneous Diseases: An Updated Review on Topical Delgocitinib	41
Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies	40
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review	40
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	40
Catumaxomab: First Approval	40
Correction: Teprotumumab: A Review in Thyroid Eye Disease	39
Correction: Ifupinostat: First Approval	39
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	39
Ensitrelvir Fumaric Acid: First Approval	38
Current and Emerging Treatments for Acid Sphingomyelinase Deficiency	38
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	38
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	38
Fezolinetant: First Approval	37
Futibatinib: First Approval	37
Avacincaptad Pegol: First Approval	36
Polidocanol in Sclerotherapy for Lymphovenous Disorders: Mechanisms, Clinical Uses, and Future Prospects	36
Becotatug Vedotin: First Approval	36
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	36
Atrasentan: First Approval	35
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	35
Antifungal Treatment Regimens as Primary Therapy for Invasive Aspergillosis: A Systematic Review and Network Meta-analysis	35
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale	35
Eye Involvement and Management in Inherited Epidermolysis Bullosa	34
Lotilaner Ophthalmic Solution 0.25%: First Approval	34
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	34
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	34
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	34
Zastaprazan: First Approval	33
Correction: Iptacopan: First Approval	33
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	33
Imetelstat: First Approval	33
Zeprumetostat: First Approval	33
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	32
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	32
Oral Gut-Restricted Targeted Therapy for IBD: A Pipeline Review	32
Beremagene Geperpavec: First Approval	32
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	32
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	31
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	31
Acknowledgement to Referees	31
Managing Pain in Fibromyalgia: Current and Future Options	31
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	30
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	30
Mavorixafor: First Approval	30
Etripamil: First Approval	30
Crinecerfont: First Approval	30
Sepiapterin: First Approval	30
Revumenib: First Approval	29
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	29
Retifanlimab: First Approval	29
EGFR Exon 20 Insertion–Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions	29
Diagnosis and Treatment of AL Amyloidosis	29
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	28
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	28
Nogapendekin alfa Inbakicept: First Approval	28
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	28
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	28
Methadone for Cancer Pain Management in Children: A Review of Literature	27
Correction to: Sparsentan: First Approval	27
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	27
Correction to: Spesolimab: First Approval	27
Onradivir: First Approval	27
Keverprazan Hydrochloride: First Approval	26
Correction: Zastaprazan: First Approval	26
Ravulizumab: A Review in Generalised Myasthenia Gravis	26
Antibacterials with Novel Chemical Scaffolds in Clinical Development	26
Remdesivir: A Review in COVID-19	26
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	25
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	25
Tradipitant: First Approval	25
Zolbetuximab: First Approval	25
Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management	25

A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation	25
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	25
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	25
Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity	25
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clos	24
Marstacimab: First Approval	24
Novel Drug Therapeutics in Celiac Disease: A Pipeline Review	24
Elranatamab: First Approval	24
Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy	24
Nadofaragene Firadenovec: First Approval	24
Pucotenlimab: First Approval	23
Correction to: Mavacamten: First Approval	23
Spesolimab: First Approval	23
Lecanemab: First Approval	23
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old	23
Correction to: Rozanolixizumab: First Approval	23
Tofersen: First Approval	22
Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study	22
Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition	22
Zongertinib: First Approval	22
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions	22
Differentiating IL-23 Inhibitors in Crohn’s Disease	22
Ziftomenib: First Approval	22
Ritlecitinib: First Approval	22
Tixagevimab + Cilgavimab: First Approval	22
Comment on “Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review”	22
Antibody–Drug Conjugates in Non-small Cell Lung Cancer	22
Amubarvimab/Romlusevimab: First Approval	22
New Developments in Glucagon Treatment for Hypoglycemia	21
Eplontersen: First Approval	21
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders	21
Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’	20
Large Vessel Vasculitis: Recent Advances in Pathophysiology and Targeted Therapies	20
Valoctocogene Roxaparvovec: First Approval	20
Benefits and Liabilities of Benzodiazepines and Z-Drugs: What We Know and What We Don’t Know	20
Correction to: Ozanimod: A Review in Ulcerative Colitis	20
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis	20
Talquetamab: First Approval	20
Trastuzumab Rezetecan: First Approval	20
Elafibranor: First Approval	20
Paltusotine: First Approval	19
Dimdazenil: First Approval	19
Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort St	19
20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults	19
Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline	19
Gepotidacin: First Approval	19
Iptacopan: First Approval	19
Tunlametinib: First Approval	19
Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments	19
A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?	19
Vamorolone: First Approval	19
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors	19
Pharmacological, Natural and Emerging Therapies for Meibomian Gland Dysfunction: A Review	18
PCSK9 Inhibitors: A Potential Priority Choice for Lipid Management in Patients with Diabetic Kidney Disease	18
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies	18
Correction: Senaparib: First Approval	18
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy	18
Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action	18
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections	18
PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis	18
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder	18
Mirvetuximab Soravtansine: First Approval	18
Sipavibart: First Approval	18
Motixafortide: First Approval	18
Sulbactam/Durlobactam: First Approval	17
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians	17
Biased Kappa-opioid Agonist Strategies in Pain Management: Approaches to Clinical Benefits with Reduced Adverse Effects	17
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions	17
Tegileridine: First Approval	17
Nemolizumab: First Approval	17
Tirzepatide: First Approval	17
Drug-Induced Pigmentation: A Review	17
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis	17
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?	17
Clesrovimab: First Approval	17
Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective	17
Results from Expanded Access Programs: A Review of Academic Literature	17
Linzagolix: First Approval	17
Drugs in Development to Treat IgA Nephropathy	17
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials	17
Fitusiran: First Approval	17
Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?	16
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside	16
Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms	16
Vimseltinib: First Approval	16
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy	16
Vonoprazan: A Review in Helicobacter pylori Infection	16
HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic	16
Pirtobrutinib: First Approval	16
In Search of the Optimal Antithrombotic Regimen for Intracerebral Hemorrhage Survivors with Atrial Fibrillation	16
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review	16
Rezvilutamide: First Approval	16
The Potential of RNA Therapeutics in Treating Cardiovascular Disease	16
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis	16
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota	16